clinical trial · NCT07682272
A Trial of SHR-8068 Combined With Adebrelimab and Apatinib in Perioperative Treatment of Resectable Hepatocellular Carcinoma
Suzhou Suncadia Biopharmaceuticals Co., Ltd.·phase2·not yet recruiting·n = 120
Resectable Hepatocellular Carcinoma With Intermediate or High Recurrence RiskSHR-8068 InjectionAdebrelimab InjectionApatinib Mesylate Tablets
brief summary
This study is conducted to evaluate the efficacy and safety of SHR-8068 combined with Adebrelimab and Apatinib compared with Adebrelimab combined with Apatinib in perioperative treatment of resectable hepatocellular carcinoma with intermediate or high recurrence risk.
started
Jul 1, 2026
primary completion
Jul 1, 2027
completion
Jul 1, 2029
last updated
Jul 2, 2026
official title
A Randomized, Open-label, Multicenter Phase II Study of SHR-8068 Combined With Adebrelimab and Apatinib for Perioperative Treatment in Resectable Hepatocellular Carcinoma With Intermediate or High Recurrence Risk
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol